MNTA—I would suggest that your experience with ZGEN has colored your view of biotech buyouts and that, as a result, you’re now painting with too broad a brush. A key distinction between ZGEN and MNTA is that the former had a dominant shareholder (Novo Nordisk) while the latter does not.
News 
Market Data 
Discover 
